Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences to Start P2 Trial Of Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing ARDS due to COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing ARDS due to COVID-19 Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"NASA","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The EASL 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Enzychem Lifesciences Corporation

    Menu

    Enzychem Lifesciences Corporation

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting

              Details:

              EC-18 (mosedipimod) is immune modulator, has unique MOA called PETA which accelerates PRR-mediated endocytosis, endosome formation, ROS generation and recycle of PRR such TLR4 so that EC-18 duration of inflammatory immune response by removing PAMP associated danger signals.

              Lead Product(s): Mosedipimod

              Therapeutic Area: Gastroenterology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting

              Details:

              The primary efficacy endpoint demonstrated that the median duration of SOM (defined as WHO Grades 3 or 4) from baseline through short-term follow-up period (STFU) was 0.0 days in the EC-18 group versus 13.5 days in the placebo group (100% reduction).

              Lead Product(s): Mosedipimod

              Therapeutic Area: Gastroenterology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis

              Details:

              The primary efficacy endpoint demonstrated that the median duration of SOM from baseline through short-term follow-up period was 0.0 days in EC-18, an immunomodulator, group versus 13.5 days in the placebo group (100% reduction).

              Lead Product(s): Mosedipimod

              Therapeutic Area: Oncology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis

              Details:

              EC-18 is in clinical development in Phase 2 clinical trials in chemoradiation-induced oral mucositis and COVID-19. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.

              Lead Product(s): Mosedipimod

              Therapeutic Area: Gastroenterology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis

              Details:

              Phase II trial of EC-18 is a synthetic monoacetyldiaglyceride treat oral mucositis in individuals with concomitant chemo-irradiation for mouth, hypopharynx, oropharynx, and nasopharynx cancers.

              Lead Product(s): Mosedipimod

              Therapeutic Area: Oncology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program

              Details:

              Enzychem's lead compound, EC-18, is an immunomodulator that rapidly resolves inflammation and restores immune homeostasis by accelerating the intracellular trafficking of pattern recognition receptor-bound pathogenic invaders or endogenous danger signals.

              Lead Product(s): EC-18

              Therapeutic Area: Pharmacology/Toxicology Product Name: EC-18

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institutes of Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The EASL 2021

              Details:

              Poster titled "First in-class, orally active Toll-like receptor signaling inhibitor mosedipimod (PLAG) attenuates molecular, biochemical and histologic features of nonalcoholic steatohepatitis (NASH) in vitro and in vivo" will be presented at the EASL Congress 2021.

              Lead Product(s): Mosedipimod

              Therapeutic Area: Gastroenterology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)

              Details:

              Poster titled Titled "TLR Signaling Inhibition with Mosedipimod" will be presented at the conference. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.

              Lead Product(s): Mosedipimod

              Therapeutic Area: Gastroenterology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage

              Details:

              NASA’s Human Research Program has awarded $150K in grant funding to conduct research on its lead compound EC-18, and how it impacts astronaut health and performance during future long-duration missions beyond low-Earth orbit.

              Lead Product(s): Mosedipimod

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: EC-18

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: NASA

              Deal Size: $0.1 million Upfront Cash: Undisclosed

              Deal Type: Funding January 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Enzychem Lifesciences Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021

              Details:

              At Biotech Showcase 2021, the company will provide a corporate update for its clinical programs, specifically its Phase 2 COVID-19 study and its Phase 2 clinical trial of EC-18 in Chemoradiation-induced Oral Mucositis, which will report results in the first half of this year.

              Lead Product(s): Mosedipimod

              Therapeutic Area: Gastroenterology Product Name: EC-18

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY